# Case Western Reserve University: Phase 2 study completed, 108 enrolled (HIV/AIDS, Lipohypertrophy)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Case Western Reserve University |
| Sponsor type | Academic and hospital |
| Study | Effects of Semaglutide in HIV-Associated Lipohypertrophy |
| NCT ID | NCT04019197 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | HIV/AIDS; Lipohypertrophy; Obesity |
| Intervention types | drug |
| Target enrollment | 108 |
| Site countries | United States |
| Posted | 2019-07-15 |
| Planned start | 2019-05-16 |
| Event | Completed |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 108 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04019197). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.